Nexavar (Sorafenib) Granted FDA Priority Review for RAI-refractory Differentiated Thyroid Cancer | Zendy

AI Assistant Blog Pricing

Open Access

Nexavar (Sorafenib) Granted FDA Priority Review for RAI-refractory Differentiated Thyroid Cancer

Publication year - 2013

Publication title -

oncology times

Language(s) - Uncategorized

Resource type - Journals

eISSN - 1548-4688

pISSN - 0276-2234

DOI - 10.1097/01.cot.0000435401.50699.58

Subject(s) - sorafenib , thyroid cancer , refractory (planetary science) , medicine , cancer , oncology , cancer research , hepatocellular carcinoma , biology , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.